Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone relapse prevention discontinuation study in children and adolescents with conduct disorder
NL-OMON38142Phase 4Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in conduct disorder (CD) comparing Continued risperidone with Discontinuation to placebo (2 arms). Primary endpoints: Clinical response at endpoint and Relapse prevention during double-blind discontinuation. Planned start Jun 2012; status: not yet recruiting.
02
Drugs
risperidone
03
Conditions
conduct disorder (CD)
Beyond the preview
Go deeper on NL-OMON38142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38142.